News
Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations.
Eli Lilly launched the pre-filled injector pen of its blockbuster weight-loss drug Mounjaro for 14,000 rupees (nearly $160) ...
Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...
CNBC's Silvia Amaro takes a look at the rise and fall in Novo Nordisk shares.
This article covers key health news including Primary Health Properties securing a takeover bid for Assura, Novo Nordisk's ...
Cambridge-based Biogen is looking to the growth of its Alzheimer’s drug Leqembi to offset the decline of its multiple ...
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could ...
16h
TipRanks on MSNNovo Nordisk’s Semaglutide Study: A Potential Breakthrough for Kidney Health
Novo Nordisk (($DE:NOVA)) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk recently completed a clinical study ...
Forever chemicals —also known as per- and polyfluoroalkyl substances, or PFAs, that don’t break down, but linger in the ...
Leaders at Eli Lilly believe heavy investment in the company's manufacturing footprint “sets a high standard that newcomers ...
Novo Nordisk A/S (NYSE:NVO) is among the. Novo Nordisk A/S (NYSE:NVO) lowered its operating profit growth projections to ...
We read with interest the Correspondence by Zhiqi Yao and colleagues1 published in The Lancet Diabetes & Endocrinology, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results